Research fellow

Katja Anita Oppelt

Curriculum vitae

  • Since 08/2016 Research Associate at Leibniz Institute for Prevention Research and Epidemiology – BIPS
  • 01/2015 - 06/2016 Masterprogramme Public Health at Lund University, Sweden
  • 08/2014 - 01/2015 Masterprogramme Public Health with Health Economics at Gothenburg University, Sweden
  • 01/2013 - 07/2014 Employee in a community pharmacy at Johannes Apotheke, Hannover
  • 09/2011 - 08/2012 Pharmacist in training at Mozart Apotheke, Berlin and Federal Office of Consumer Protection and Food Safety, Berlin
  • 10/2006 - 04/2011 Study of Pharmacy at University of Münster

Research interests

  • Pharmacoepidemiology
  • Cancer Epidemiology
  • Drug Safety

Memberships

Projects

Selected publications

  • Articles with peer-review

  • Oppelt KA, Luttmann S, Kraywinkel K, Haug U. Incidence of advanced colorectal cancer in Germany: Comparing claims data and cancer registry data. BMC Medical Research Methodology. 2019;19:142.
    https://doi.org/10.1186/s12874-019-0784-y
  • Oppelt KA, Haug U. Schmerztherapie bei Darmkrebspatienten - Längsschnittanalysen auf Versichertendaten basierend. Der Onkologe. 2018;24(11):848-860.
    https://doi.org/10.1007/s00761-018-0468-y
  • Presentations at scientific meetings/conferences

  • Oppelt KA, Kuiper J, Ingrasciotta Y, Lentile V, Herings R, Trifirò G, Haug U. Real-world data on the use of biologics in the treatment of colorectal cancer: Comparison between three European countries. 14. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 11.-13. September 2019, Ulm.
  • Oppelt KA, Kuiper J, Ingrasciotta Y, Lentile, Herings R, Trifirò G, Haug U. Real-world data on the use of biologics in the treatment of colorectal cancer: Comparison between three European countries. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 24-28 August 2019, Philadelphia, USA. (Abstract published in: Pharmacoepidemiology & Drug Safety. 2019;28(S2):864)
  • Oppelt KA, Luttmann S, Kraywinkel K, Haug U. Inzidenz von fortgeschrittenem Darmkrebs: Abrechnungsdaten vs. Registerdaten. 13. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 26.-28. September 2018, Bremen.
  • Schäfer W, Oppelt KA, Haug U. Nutzung von Sekundärdaten zur Charakterisierung von "Extremen" in der Versorgung: Beispiel Koloskopie. 13. Jahrestagung der Deutschen Gesellschaft für Epidemiologie (DGEpi), 26.-28. September 2018, Bremen.
  • Posters at scientific meetings/conferences

  • Oppelt KA, Kuiper J, Ingrasciotta Y, Lentile V, Herings R, Trifirò G, Haug U. Real-world data on the use of biologics in the treatment of colorectal cancer: Comparison between three European databases. WEON 2019 - 'Healthy Ageing', 13-14 June 2019, Groningen, The Netherlands.
  • Schwarz S, Oppelt KA, Haug U. The potential of German claims data to characterize real-world treatment patterns in cancer patients - The example of crizotinib. 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 24-28 August 2019, Philadelphia, USA. (Abstract published in: Pharmacoepidemiology & Drug Safety. 2019;28(S2):221)
  • Oppelt KA, Haug U. Estimating the incidence rate of advanced colorectal cancer in Germany based on claims data. 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), 22-26 August 2018, Prague, Czech Republic.
  • Oppelt KA, Haug U. Estimating the incidence rate of advanced colorectal cancer in Germany based on claims data. 33. Deutscher Krebskongress, 21.-24. Februar 2018, Berlin. (Abstract publiziert in: Oncology Research and Treatment. 2018;41(Suppl.1):51)

For further publications please follow this link:

Prizes and awards

  • ICPE Scholarship 2019
    Internal Society for Pharmacoepidemiology (2019)
    Attending the 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management in Philadelphia, PA, USA

The responsibility for the content of this page lies with Katja Anita Oppelt.